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The simplicity and potential of minimally invasive 
testing using sera from patients makes auto-antibody 
based biomarkers a very promising tool for use in can-
cer diagnostics. Protein microarrays have been used for 
the identification of such auto-antibody signatures. 
Because high throughput protein expression and purifi-
cation is laborious, synthetic peptides might be a good 
alternative for microarray generation and multiplexed 
analyses.   
 In this study, we designed 1185 antigenic pep-
tides, deduced from proteins expressed by 642 cDNA 
expression clones found to be sero-reactive in both 
breast tumour patients and controls. The sero-reactive 
proteins and the corresponding peptides were used for 
the production of protein and peptide microarrays. Se-
rum samples from females with benign and malignant 
breast tumours and healthy control sera (n=16 per 
group) were then analysed. Correct classification of the 
serum samples on peptide microarrays were 78% for 
discrimination of ‘malignant versus healthy controls’, 
72% for ‘benign versus malignant’ and 94% for 
‘benign versus controls’. On protein arrays, correct 
classification for these contrasts was 69%, 59% and 
59%, respectively. 
 The over-representation analysis of the classi-
fiers derived from class prediction showed enrichment 
of genes associated with ribosomes, spliceosomes, en-
docytosis and the pentose phosphate pathway. Se-
quence analyses of the peptides with the highest sero-
reactivity demonstrated enrichment of the zinc-finger 
domain. Peptides’ sero-reactivities were found nega-
tively correlated with hydrophobicity and positively 
correlated with positive charge, high inter-residue pro-
tein contact energies and a secondary structure propen-
sity bias. This study hints at the possibility of using in 
silico designed antigenic peptide microarrays as an 
alternative to protein microarrays for the improvement 
of tumour auto-antibody based diagnostics. 
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Introduction 
 
Breast cancer is the leading tumour type in women, 
with an estimated 1 million new cases worldwide each 
year (Pisani et al. 2002; Sturgeon et al. 2008). An in-
creased survival rate is highly correlated with an early 
detection of malignancy, making diagnostics a critical 
tool in cancer prevention. Over the past decades sev-
eral diagnostic tools have been developed and used in 
screening programmes, such as mammography, ultra-
sound imaging and magnetic resonance imaging (MRI) 
(Piura & Piura 2011). These are all able to detect prob-
able malignancies; however, definitive answers still 
require biopsy and histopathological examination. 
 Blood-based biomarker discovery is an emerg-
ing field of cancer research which seeks to identify 
specific and sensitive markers, enabling clinicians to 
make decisions with great accuracy and reliability. 
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Detection of tumour-associated auto-antibodies from a 
few drops of blood may provide a possibility to screen 
patients with the suspicion of breast cancer or even 
before, through periodical examination. Tumour-
associated antibodies can be identified through selec-
tive binding to special antigens, called ‘tumour-
associated antigens’ (TAAs). TAAs derived from aber-
rantly expressed proteins during the onset and progres-
sion of cancer development, display ‘non-self’ epi-
topes which trigger the immune system to remove 
them. The observed antigenicity has been attributed to 
multiple features of cancer growth, including accumu-
lated mutations in cancer cells (e.g. point mutations, 
translocations), overexpression and translation of 
‘differentiation genes’ or improper post-translational 
modification (Backes et al. 2011). These molecules 
usually possess important functions in tumourigenesis, 
such as regulation of the cell cycle, cell proliferation 
and apoptosis (Ullah & Aatif 2009). Previous studies 
have already elucidated several TAAs from the sera of 
breast cancer patients, such as MUC1, HSP90, HER2/
neu, c-myc, NY-ESO1/LAGE1 and Lipophilin B 
(Carter et al. 2003, Chapman et al. 2007, Conroy et al. 
1995, Disis et al. 1994). Auto-antibodies against p53 
tumour suppressor proteins were also detected in the 
sera of 9-26% of women with breast cancer 
(Montenarh 2000). However, it has been shown that 
through assaying of sera, reactivity for a single TAA is 
neither sensitive nor specific enough to discriminate 
between healthy individuals and cancer patients. Thus 
a combination of multiple TAAs would be preferred to 
generate a diagnostic classification tool. 
 Several methods have been developed to iden-
tify, screen and validate discriminative TAAs. SEREX 
(Serological Analysis of Recombinant Expressed 
cDNAs) and SERPA (Serological Proteomics Analy-
sis) are such methods, employed to identify de novo 
TAAs directly from tumour cells (Lu et al. 2008). Al-
though these methods have been used successfully to 
uncover new antigens (Hamrita et al. 2008, Qian et al. 
2005, Stempfer et al. 2010), the drawback of these 
technologies is that they are labour intensive and only 
applicable on a small scale. Higher throughput meth-
ods such as protein macro- and microarrays allow for 
simultaneous quantification of serum reactivity of 
thousands of proteins. One of the major challenges of 
these applications is the requirement of a huge number 
of in-frame cDNA clones and the subsequent expres-
sion and purification of the cognate proteins from 
them. The physicochemical properties (e.g. length vs. 
hydrophobic domains) of expressed proteins are usu-
ally highly variable and displaying the associated reac-
tive epitopes upon immobilisation can be hardly con-
trolled. 
 Peptide microarrays represent another alterna-
tive solution as shorter peptide sequences may reca-
pitulate the biological function (i.e. the antigenic epi-
tope) of the corresponding protein (Cretich et al. 2006; 
Uttamchandani & Yao 2008). Production of synthetic 
peptides is a well established technique and using pep-
tide arrays as a potential alternative to protein arrays 
would have several advantages. The concept of the 
peptide array was first proposed by Southern in 1988 
(Southern 1988). Techniques like photolithographic 
peptide synthesis on a glass surface (Fodor et al. 1991) 
and the SPOT-synthesis technology (Frank 2002) have 
accelerated the applications of synthetic peptides in 
microarray experiments (Shin et al. 2005). 
 In this report we evaluate the performance of a 
SPOT-synthesized peptide microarray. This technol-
ogy utilizes the traditional fmoc chemistry to synthe-
size peptides in single droplets immobilized on the 
surface of slides.  Based on a semi-empirical method 
developed by Kolaskar and Tongaonkar (Kolaskar & 
Tongaonkar 1990), we deduced antigenic peptides 
from a set of previously identified, protein microarray-
derived, antigenic proteins. We probed these peptides 
with sera from breast cancer patients and individuals 
with benign breast nodules, whilst compared them 
with samples from healthy donors. We further evalu-
ated the identified sero-reactive peptides using bioin-
formatics tools and defined panels of TAAs, which are 
able to discriminate between samples of healthy con-
trol, malignant and benign tumours. 
 
Materials and Methods 
 
Serum Samples 
Serum samples were obtained after the consent of the 
breast cancer patients and healthy female volunteers. 
The samples were then stored at -80°C. The study was 
approved by the Ethics Committee of the Medical Uni-
versity of Vienna, the General Hospital of Vienna 
(study number: 143/2007) and all procedures were car-
ried out in compliance with the Helsinki Declaration. 
For the protein and peptide microarray analysis of 
breast cancer serum biomarkers, 48 serum samples 
(malignant n=16; benign n=16; healthy n=16) were 
used. The clinical and the pathological cohorts of the 
serum samples are described in Table 1. All the 16 ma-
lignant samples were collected from patients diag-
nosed with invasive ductal carcinoma and tested posi-
tive to HER2/neu. Furthermore, the benign samples 
were collected from patients diagnosed with fibroade-
noma. Healthy control serum samples (n=16, mean age 
76.9±7.15), were collected from healthy volunteers 
who presented no personal or familial history of breast 
or ovarian cancer. 
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 Protein extraction and purification 
In an earlier study, 642 clones were identified from a 
collection of 38,016 cDNA expression E. coli clones 
(hEx1 library (Bussow et al. 2000)), which reacted 
positively to the sera from the breast cancer patients 
and the healthy control individuals. For the recombi-
nant protein expression in E. coli and protein purifica-
tion, the procedure developed by Stempfer et al. was 
followed (Stempfer et al. 2010). In brief, the cDNA 
expression clones were cultured in 96 deep well plates 
and were induced by an autoinduction strategy for re-
combinant protein production. The expressed His-
tagged proteins were then purified using Ni-NTA aga-
rose and eluted in microarray spotting buffer (50 mM 
KH2PO4 and 50 mM K2HPO4, pH 8.0, 500 mM imida-
zole, 0.01% SDS and 0.01% NaN3). 
 
Design of Antigenic Peptides 
Peptides corresponding to the 642 reactive proteins 
were designed as an alternative to the recombinant pro-
teins found reactive in the initial membrane screening. 
To predict the antigenic peptides, the EMBOSS tool 
“Antigenic” (http://liv.bmc.uu.se/cgi-bin/emboss/
antigenic) was used. The minimum length of the pre-
dicted peptide sequences is 6 amino acids (aa). The 
“Antigenic” tool employs a semi-empirical method 
developed by Kolaskar and Tongaonkar for the selec-
tion of antigenic peptide sequences. This method uses 
the physicochemical properties of amino acid residues 
and their frequencies of occurrence in experimentally 
known segmental epitopes to predict antigenic deter-
minants on proteins (Kolaskar & Tongaonkar 1990). 
 The DNA sequence was available for 596 of 
the 642 clones. Of those, 581 clones were unique and 
used for antigenic peptide prediction. The default set-
tings of the “Antigenic” tool were used, and for each 
unique clone sequence, 2-3 different peptides were 
selected based on antigenicity score and peptide-
length. In trying to achieve uniform synthesis, peptides 
sized 8-10 aa were selected. Based on the maximum 
antigenicity score, antigenic peptides which were 
longer than 10 aa were shortened. For antigenic motifs 
shorter than 8 aa peptides, N terminal aa’s correspond-
ing to the template sequence were added. In addition, 
tetanus specific antigenic peptides were designed for 
the NCBI reference sequence NP_783831; 56 tetanus 
specific peptides were selected from all potential anti-
genic peptides based on their maximum antigenicity 
score. Furthermore, peptides of 10 aa in length were 
selected for synthesis as described above. 
 In order to find over-represented motifs in the 
peptide set, sequences were submitted to MEME motif 
search web-based tool (http://meme.nbcr.net). The mo-
tif was considered as ‘enriched’ if it had at least 5 se-
quences (sites) with an E-value less than 0.001. Motif 
searching was also performed on peptide sequences 
with high sero-reactivity (defined as median log2 in-
tensities >13 of all 48 samples analysed; min.: 6.21; 
max.: 15.84). 
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Benign (n=16) 
Malignant 
(n=16) 
Age (years)a 52.5±4.9 53.75±8 
Gradingb  
G1 - 1 
G2 - 5 
G3 - 10 
Oestrogen receptor 
positive 
- 9 
pT stagec  
pT1; pT1b; pT1c; 
pT1mic; pT2 
- 
3; 3; 7; 
1; 2 
pN staged  
pN0; pN1; pN1a; 
pN2; pN2a; pN3 
- 
7; 1; 1; 
1; 3; 2 
Metastasis stagee: 
M0 
- 6 
Menopause statusf  
Pre-menopause 3 4 
Post-menopause 8 11 
aThe age of the patients is represented as a mean 
(age±standard deviation). 
bG1 (low-grade), G2 (intermediate grade) and G3 (high-
grade). Low-grade tumours are usually slow growing and 
are less likely to spread. High-grade tumours are likely to 
grow more quickly and are more likely to spread. 
cpT1: Tumour 2.0 cm or less in dimension; pT1b: Tumour 
between 0.5 and 1 cm in dimension; pT1c: Tumour be-
tween 1.0 and 2.0 cm in dimension; pT1mic: Microinva-
sion 0.1 cm or less in dimension; pT2: Tumour between 
2.0 and 5.0 cm in dimension. 
dpN stage: information available for 15 patients. pN0: No 
regional lymph node metastasis; pN1: Metastasis to mov-
able ipsilateral axillary lymph node(s); pN1a: Only micro-
metastasis (none larger than 0.2 cm); pN2: Metastasis to 
ipsilateral axillary lymph node(s) fixed to each other or to 
other structures; pN2a. Metastasis in 4-9 axillary lymph 
nodes, including at least one that is larger than 2 mm; pN3: 
Metastasis to ipsilateral internal mammary lymph node(s). 
eMetastasis stage: information from 6 patients. M0: No 
distant metastasis. 
fInformation from 11 benign and 15 malignant samples.  
Table 1. Clinical and pathological data of the patient-study 
cohort. Benign and maligant samples were collected from 
patients with fibroadenomas and invasive ductal carcinoma, 
respectively. 
 Microarray production 
The procedure for the protein microarray production 
has been described in our previous study (Stempfer et 
al. 2010). In brief, the protein microarrays were gener-
ated using the purified recombinant proteins obtained 
from the cDNA expressing E. coli clones. These puri-
fied proteins were spotted using an Omnigrid arrayer 
(GeneMachines, San Carlos, CA) with SMP 3 pins 
(TeleChem International Inc., Sunnyvale, CA) under 
adjusted air humidity; between 55% and 60%. Spots 
were printed in duplicates on ARChip Epoxy slides 
(Preininger et al. 2004) and each microarray contained 
4 identical subarrays. The crude protein extract of the 
E.coli host was used for positive control spots, and 
plain buffer spots were used as negative controls.  
For the generation of peptide microarrays, 1212 clone-
specific and 56 tetanus specific short peptides were 
synthesized using SPOT synthesis technology (JPT 
Peptide Technologies GmbH, Berlin, Germany). Ami-
nooxy-acetylated peptides were synthesized in parallel 
on cellulose membranes. Once the de-protection of the 
side chain was achieved, the solid phase-bound pep-
tides were transferred to 96 well microtitre filtration 
plates (Millipore, Bedford, USA). These peptides were 
cleaved from the cellulose membranes using 200 ml of 
aqueous triethylamine (0.5% v/v). The triethylamine-
peptide solution was filtered and evaporated under re-
duced pressure to remove the solvent. This was fol-
lowed by re-dissolving the resultant peptide deriva-
tives (50 nmol) in 25 mL of spot buffer (70% DMSO, 
25% 0.2 M sodium acetate pH 4.5, 5% v/v glycerol). 
The re-dissolved peptide solution was then transferred 
into 384 well microtitre plates and used for the genera-
tion of the peptide arrays.  Two droplets of 0.5 nL pep-
tide solution (1 mM) were immobilized in triplicates 
on ARChip Epoxy slides (Preininger et al. 2004), con-
taining 4 identical sub-arrays on each slide. For the 
immobilization of the peptide solution, a non-contact 
printer Nanoplotter (GESIM, Groberkmannsdorf, Ger-
many) fitted with a piezoelectric NanoTip (GESIM) 
was used. Apart from the peptides derived from the 
cDNA clone-proteins, human Immunoglobulins (Igs) 
(IgA, IgE, IgG and IgM) and 56 tetanus toxin (TT) 
specific peptides were also immobilized on the peptide 
microarrays. The human Igs and TT specific peptides 
were used as positive controls, while the empty buffer 
spots were used as negative controls. 
 
Microarray processing 
The microarrays were blocked with DIG easy Hyb 
(Roche Applied Science, Vienna, Austria) for 30 min 
and then washed twice in Phosphate Buffered Saline 
with 0.1% Tween 20 (PBST) for 5 min. Breast cancer 
serum samples (benign; n=16 and malignant; n=16) 
and control sera (n=16) diluted in a 1:10 ratio with 
PBST were applied onto the microarrays and incubated 
for 2 hours. The microarrays were then washed twice 
in PBST for 5 min. This was followed by incubation 
for 30 min with goat anti human IgG detection anti-
body, fluorescently labelled with Alexa647 dye 
(Invitrogen, Vienna, Austria), diluted 1:500 in 
PBST+3% non-fat dry milk powder. Later, the mi-
croarrays were washed twice in PBST for 5 min. The 
array images of the processed slides were then cap-
tured using an Axon Genepix 4000A microarray scan-
ner (Molecular Devices, Union City, CA). 
 
Data analysis 
Fluorescent intensity values (median after subtraction 
of the local background) were calculated from the 
scanned images using the Genepix software 
(Molecular Devices). Statistical analysis of the mi-
croarray experiments was performed using the BRB-
ArrayTools software 3.8.1 [http://linus.nci.nih.gov/
BRB-ArrayTools.html] developed by Dr. R Simon and 
Amy Peng Lam (Simon et al. 2007). The log2-
transformed values of the signal intensities obtained 
from the scanned images of the processed microarrays 
were used for the analysis. The peptide microarray 
data were normalized using the “house-keeping gene” 
normalisation option within BRB-ArrayTools using 
the “Tetanus peptides” and “Igs” spots as normalisa-
tion features. For the data from protein microarrays, a 
global normalization was used to normalize each array 
using the relative median over all the log intensity val-
ues within one experiment. To identify the proteins/
peptides expressed differentially between classes, a 
random-variance t-test was applied to the data sets 
(Wright & Simon 2003). Significance of differentially 
expressed proteins/peptides were then ranked using the 
p-value (0.05 and 0.01 for protein and peptide microar-
ray data, respectively) from the univariate test. Further 
statistical data analysis was performed using R version 
2.6.2 (R Development Core Team 2005). 
 For defining a classifier set of antigenic pro-
teins and peptides, the class prediction tools imple-
mented in BRB-ArrayTools were used and leave-one-
out cross validation (LOOCV) was conducted. Differ-
ent classification algorithms (compound covariate, k 
nearest neighbour (k=1 and k=3), nearest centroid, 
support vector machines, diagonal linear discriminant 
analyses and Bayesian compound covariate prediction) 
were run for model generation. The model incorpo-
rated the features that were differentially expressed 
among all the microarray-features at the 0.01 and 0.05 
significance level as assessed by the random variance t
-test, respectively (Wright & Simon 2003). We esti-
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were used as reference set and a ‘hypergeometric dis-
tribution test’ was performed for computing P-values. 
The significance value of 0.05 (Benjamini and Ho-
chberg adjusted) was chosen.  
 
Results 
 
Antigenic motif search 
Out of 642 clone-proteins, which were used for the 
protein microarray production, sequences of 596 pro-
teins were available. All 3 possible reading frames of 
DNA sequences coding for proteins were collected and 
checked for the longest uninterrupted ORF sequence. 
After eliminating the duplicates, we found 581 unique 
sequences which were used for antigenic motif search. 
Using the “Antigenic” tool we obtained 4492 antigenic 
peptides for these 581 clone-sequences, resembling an 
average of 7.73 peptides per clone. When the length of 
the 4492 antigenic peptides were plotted against fre-
quency of occurrence, a high frequency of occurrence 
was observed with peptides of length ranging from 6 to 
20 amino acids (Figure 1) and also, a uniform distribu-
tion of antigenic motifs were found along the 581 
clone-sequences subjected to peptide design (Figure 
2). 
 Of the 4492 antigenic motifs 2866 were 
unique motifs. From the latter, 2-3 peptides per clone 
mated the prediction error for each model using 
LOOCV, as described by Simon and colleagues 
(Simon et al. 2003). For each LOOCV training set, the 
entire model building process was repeated, including 
the peptide and protein selection process. We also 
evaluated whether the cross-validated error rate esti-
mate for a model was significantly less than one would 
expect from random prediction. The class labels were 
randomly permuted and the entire LOOCV process 
was repeated. The significance level is the proportion 
of the random permutations that gave a cross-validated 
error rate no greater than the cross-validated error rate 
obtained with the real data. Cross-Validation receiver 
operating curve (ROC) analyses from the Bayesian 
Compound Covariate Predictor were conducted and 
the ‘area under the curve’ (AUC) values were calcu-
lated as implemented in ‘BRB-ArrayTools’ class pre-
diction tools. 
 
Over-representation analysis 
An over-representation analysis (ORA) of the classifi-
ers derived from the microarray experiments was per-
formed using the gene set enrichment analysis tool 
“GeneTrail” (Keller et al. 2008). The classifiers from 
the peptide microarray analysis were traced back to the 
proteins they were derived from and the ORA was per-
formed using the corresponding gene Ids. Similarly, 
the classifiers from the protein array analysis were 
used for the ORA. For ORA, a reference set was com-
pared to the test sets (genes corresponding to the clas-
sifiers). All annotated human genes (NCBI GeneIDs) 
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Figure 1. Length distribution of 4492 peptides. The figure 
shows the frequency of occurrence (Y-axis) of the peptides 
with regards to the length of the antigenic motif (X-axis). A 
relatively high frequency of occurrence was observed for 
the short-length peptides. 
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Figure 2. Distribution of 4492 antigenic motifs along the 
581 clone sequences. The x-axis depicts the start amino acid 
position within the targeted clone-sequences; on the y-axis, 
the length of the antigenic-peptides is depicted.  A uniform 
distribution of the antigenic motifs was observed along the 
clone sequences. Density of plotted antigenic motifs is high-
est for short peptides (<20mers; y-axis).  
were selected which had maximum scores (1.3 to 
0.987) and thus identified 1212 peptides. Out of these 
1212 peptides, 53%, 33.7% and 13.2% of the peptides 
were 8-10, 7-14 and more than 14 aa long, respectively 
(Table 2). Peptides with lengths ranging 6 to14 were 
present at highest frequency compared to the longer 
peptides (Figure 3). These 1185 single peptides, in-
cluding the human Igs and the 56 TT specific peptides 
were used for the peptide array production. 
 
Serum reactivity of ‘antigenic’ peptide arrays 
Median intensities of each duplicate peptide spot from 
the 48 microarray analyses were calculated and used to 
evaluate the correlation of serum-reactivity towards the 
‘antigenicity score’ and the influence of aa addition or 
removal from the antigenic motif (peptide lengths were 
adjusted in order to synthesize and spot 8-10 aa pep-
tides; see Methods). We could not find any correlation 
of microarray signal intensities with ‘length adjust-
ment of peptides’ and ‘antigenicity scores’ (Figure 4).  
 Furthermore peptides were converted into nu-
merical representations and subjected to linear correla-
tion analysis with median and maximum intensities. 
Overall 3697 amino acid and sequence parameters 
were used for this alternative representation. Of these, 
the majority was derived from AAINDEX (http://
www.genome.jp/aaindex/), augmented by a few fea-
ture descriptors commonly used in QSAR analysis and 
basic amino acid statistics, including simplified alpha-
bets (Söllner 2006). B-cell antigenicity was estimated 
using a previously presented regression model and se-
quence entropy using a composition biased method 
(Sollner et al. 2008). Susceptibility to proteasomal 
processing was assessed using netChop (Keşmir et al. 
2002). Affinity for 43 MHC alleles was predicted us-
ing netMHC (Lundegaard et al. 2008) and highest af-
finities mapped to respective supertypes. For all single 
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Figure 3. Length distribution of 1185 single peptides. The 
frequency of occurrence (Y-axis) of the peptides with re-
gards to the length of the antigenic motif (X-axis) is shown. 
Figure 4. Antigenic reactivity derived from 48 samples. Median peptide array intensities (log2 transformed) were plotted ver-
sus the ‘antigenicity score’ (A), and the ‘length adjustment’ (denoted “pos”). Positive values correspond to the number of aa 
added, negative values to aa removed from the antigenic motifs for the generation of 8-10aa peptides for array spotting (B). 
  
Length (aa) 
Number of 
peptides 
Number of 
clones 
8-10 643 329 
7-14 409 79 
>14 160 55 
Table 2. Number of peptides with regards to the length of 
the antigenic motifs and the number of the corresponding 
clones. 
ties. A scatter plot of the maximally correlated feature, 
a hydrophobicity scale by Wilce et al. (Wilce et al. 
1995), is shown in Figure 5. The scatter plot clearly 
supports a linear dependency and a selection of other 
substantially correlated peptide properties is listed in 
Table 3. Measured median intensities are particularly 
negatively correlated with hydrophobicity and posi-
tively correlated with both positive charge and high 
inter-residue protein contact energies. The existence of 
a possible secondary structure propensity bias is also 
apparent. 
 
Motif enrichment analysis 
Motif enrichment analysis was performed on our mi-
croarray peptide set (1185 peptides) using the MEME 
motif discovery tool (Bailey & Elkan, 1994; http://
meme.sdsc.edu/meme/). The most significant and 
highly represented motif found was similar to Zn-
finger domains of Zn-H2C2-type (Fig. 6A, see 
pfam13465: zf-H2C2_2). The motif logo consisted of 
26 sequences and the diagram clearly depicts the 
highly weighted two central cysteines, separated by 
two other amino acids. Seemingly the first two amino 
acids (proline and tyrosine) also have a conserved role 
to constitute these domains (Figure 6A). In a second 
screen, only those peptides were considered in the 
analysis that gave high intensity values (median log2 
>13). The analysis of highly reactive peptides eluci-
dated similar results: the only significantly enriched 
motif was again the previously identified Zn-finger 
aa parameters, averages over the entire peptide, N- and 
C-terminal residues were computed. 
 The features with the highest positive or nega-
tive correlation (in the order of -0.5 and +0.45, respec-
tively) all originate among physico-chemical proper-
ties, in particular hydrophobicity, inter-residue contact 
energy, secondary structure and charge related proper-
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Figure 5. Scatter plot of the peptides parameterized using 
the hydrophobicity scale by Wilce et al. (WILM950101 on 
x-axis) versus the median peptide array intensities (log2 
transformed on y-axis). 
Parameter 
Correlation to 
median  
intensity 
Type URL 
WILM950101 -0.53 negative http://www.genome.jp/dbget-bin/www_bget?aaindex:WILM950101 
COWR900101 -0.53 negative http://www.genome.jp/dbget-bin/www_bget?aaindex:COWR900101 
GUOD860101 -0.52 negative http://www.genome.jp/dbget-bin/www_bget?aaindex:GUOD860101 
NAKH920108 -0.52 negative http://www.genome.jp/dbget-bin/www_bget?aaindex:NAKH920108 
JURD980101 -0.51 negative http://www.genome.jp/dbget-bin/www_bget?aaindex:JURD980101 
MONM990101 0.48 positive http://www.genome.jp/dbget-bin/www_bget?aaindex:MONM990101 
FAUJ880111 0.46 positive http://www.genome.jp/dbget-bin/www_bget?aaindex:FAUJ880111 
CHOP780207 0.46 positive http://www.genome.jp/dbget-bin/www_bget?aaindex:CHOP780207 
MIYS990102 0.45 positive http://www.genome.jp/dbget-bin/www_bget?aaindex:MIYS990102 
MIYS990101 0.45 positive http://www.genome.jp/dbget-bin/www_bget?aaindex:MIYS990101 
Table 3. Physico-chemical parameters maximally correlated with the median intensity derived from the peptide arrays proc-
essed with 48 serum samples. Correlation coefficients scale between -1 and 1, indicating negative and positive correlation, re-
spectively. 
(Figure 6B). Since only 385 sequences were used in 
this analysis these motifs were “shorter” (8 amino ac-
ids) and again clearly depicted the Zn-finger domain 
characteristics for the superfamily. The finding that Zn
-finger domains presented in our peptide array analy-
ses as highly sero-reactive, confirms their antigenicity. 
These findings are concordant with previous reports, 
which found several members of Zn-finger proteins as 
tumour-associated antigens (Ludwig et al. 2012). 
 
Microarray analysis 
The data obtained upon processing the protein and the 
peptide microarrays with the breast cancer (n=16), be-
nign fibroadenomas (n=16) and healthy control (n=16) 
sera was subjected to statistical evaluation. The class 
prediction of the samples was performed using BRB-
ArrayTools and the performance of algorithms with 
the highest correct classifications is depicted. 
 We elucidated a marker-set of 54 peptides 
(Table 1S; see supplementary data) which enabled 
78% correct classification  using the “compound co-
variate classifier” of malignant samples and healthy 
controls with 75% sensitivity and 81.2% specificity 
(Table 4). The ROC curve derived from this class pre-
diction (Figure 7A) demonstrated AUC values of 
0.758. For the prediction of the same classes on protein 
array, a marker-set of 57 proteins was deduced (Table 
2S; see supplementary data). These proteins enabled 
the 69% correct classification of the malignant samples 
and healthy controls with 62.5% sensitivity, 75% 
specificity (Table 4) and an AUC value of 0.68 
(support vector machine classifier) (Figure 7B). 
 For class prediction of the benign and malig-
nant samples on peptide arrays, we elucidated 9 pep-
tides (Table 3S; see supplementary data) which en-
abled correct classification of 72% (3-Nearest 
Neighbours classifier) with 62.5% sensitivity and 
81.2% specificity (Table 4) An AUC value of 0.6 was 
observed for this classification (Figure 7D). Similarly 
on the protein array, 17 proteins (Table 4S; see supple-
mentary data) enabled 59% correct classification (1-
Nearest neighbour) of benign and malignant samples 
with 87.5% sensitivity, 31.2% specificity (Table 4) and 
an AUC value of 0.461 (Fig. 7E) (Table 4). 
 The class prediction between the benign and 
the control samples yielded 17 peptides (Table 5S; see 
supplementary data) which gave 93.8% sensitivity and 
specificity with 94% correct classification (1-Nearest 
Neighbour classifier method) (Table 4). The observed 
AUC value of the ROC curve for this class prediction 
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Figure 6. Sequence logos of enriched motifs. (A) Sequence 
logo depicting the most significant motif (E-value: 1.0-
e100, 26 sites). (B) Analysis of peptides with high experi-
mental signal intensity (median log2>13) giving very simi-
lar results (E-value: 9.8e-23, 11 sites). MEME sequence 
logos represent probability matrices that specify the prob-
ability of each letter in all possible positions. 
Classes Microarray 
Classification 
method 
Correctly 
classified 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV NPV AUC 
Malignant 
vs. 
Control 
Peptide 
Compound 
covariate  
predictor 
78 75 81.2 0.8 0.765 0.758 
Protein 
Support vector 
machine 
69 62.5 75 0.714 0.667 0.68 
Benign 
vs.  
Malignant 
Peptide 
3-Nearest 
neighbours 
72 62.5 81.2 0.769 0.684 0.6 
Protein 
1-Nearest 
neighbour 
59 87.5 31.2 0.56 0.714 0.461 
Benign 
vs. 
Control 
Peptide 
1-Nearest 
neighbour 
94 93.8 93.8 0.938 0.938 0.852 
Protein 
Compound 
covariate 
predictor 
59 62.5 56.2 0.588 0.6 0.648 
Table 4. Class predication of benign, malignant and control samples using peptide and protein arrays. 
PPV: positve predictive value. NPV: negative predictive value. PPV and NPV correspond to the proportion of samples with 
positive and negative test results, respectively, which are correctly diagnosed.  
was 0.852 (Figure 7F). From the protein microarray 
data, we elucidated a panel of 35 proteins (Table 6S; 
see supplementary data) which enabled 59% correct 
classification (compound covariate classifier) of be-
nign and control samples; sensitivity was 62.5%, 
specificity was 56.2% (Table 4) and the corresponding 
AUC value was 0.648 (Figure 7G). Upon comparing 
the classifiers derived from all the class predictions 
performed on peptide and protein arrays, we identified 
9 overlapping proteins corresponding to the genes:, 
PCSK1,  DGKK, ZNF598, TBC1D9, TMEM199, 
EPB41L3, SAMD6, PRPF38A and C1orf9.  
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Figure 7. Cross-Validation ROC curves from the Bayesian Compound Covariate Predictor. The figures A, D and F represent 
the ROC curves obtained from the class predictions performed using the data from the peptide arrays. The figures B, E and G 
represent the ROC curves from the class predictions obtained from the protein microarray analysis. The figures C and H repre-
sent the ROC curves from the class predictions obtained from the protein array analyzed using the proteins corresponding to the 
respective peptide array classifiers. The x-axes and y-axes represent the false positive rate (1-specificity) and true positive rate 
(sensitivity), respectively. The ROC curves A, B and C represent the class prediction of malignant and control samples. The 
class predictions of benign and malignant samples are represented by the ROC curves D and E. Similarly, the ROC curves F, G 
and H represent the class prediction of the benign and control samples. 
 Using the clone-proteins (recombinantly ex-
pressed proteins from the cDNA expression clones) 
corresponding to the classifier peptides derived from 
the class prediction of malignant and control samples, 
a set of 4 proteins  (Table 7S; see supplementary data) 
were deduced which enabled a correct classification of 
66% (compound covariate classifier), with 56.2% sen-
sitivity, 75% specificity and an AUC value 0.688 
(Figure 7C). The class prediction of malignant and be-
nign samples was not possible using the clone proteins 
corresponding to the classifier peptides. The clone pro-
teins corresponding to the classifier from the class pre-
diction of benign and the control samples enabled a 
72% correct classification (compound covariate classi-
fier) of the same classes with 2 clone proteins (Table 
8S; see supplementary data). For this class prediction, 
68.8% sensitivity, 75% specificity and an AUC value 
of 0.793 (Figure 7H) were observed. 
 Higher percentages of the correct classification 
were observed on peptide arrays compared to the same 
contrasts on protein microarray data (Table 4). For ex-
ample, when malignant samples were compared to 
healthy controls, peptide arrays gave 9% more correct 
classification compared to protein arrays. Similarly, 
peptide arrays gave a 13% and 35% increasingly cor-
rect classification for the contrasts between ‘benign vs 
malignant’ and ‘benign vs controls’, respectively, 
when compared to the protein microarrays. 
 The signal intensities from all the peptide ar-
ray classifiers were compared with the ones from the 
corresponding proteins on the protein arrays. Simi-
larly, the signal intensities from all the protein array 
classifiers were compared to the ones from the corre-
sponding peptides. These comparisons failed to give 
any correlation between the peptide and protein array 
data (Figures 1S and 2S; see supplemental file). 
Over-representation analysis 
 
Peptide array classifiers 
Over-representation analysis of the genes encoding the 
classifier peptides from all class predictions on peptide 
arrays was performed using the gene set analysis tool 
“GeneTrail” (Keller et al. 2008). Out of 57 genes rep-
resenting the peptide classifiers, 3 genes, namely 
RPL7A, RPL24 and RPL6 were involved in the KEGG 
ribosome pathway. PGLS and ALDOA were found to 
be involved in the pentose phosphate pathway, while 
ISY1 and PRPF38A were involved in the spliceosome 
pathway (Table 5). Out of the 57 genes, 7 genes con-
tain a Zn-finger domain and among these 7 genes, 4 
genes contain Zn-finger domains of the Zn-H2C2-type. 
 
Protein array classifiers 
Similarly, ORA was performed using the genes encod-
ing the classifiers from all the class predictions on the 
protein array. 2 genes (RPS3A and RPS13) out of a 
total of 59 representing the protein classifiers were 
found to be involved in the KEGG ribosome pathway. 
GIT1, CHMP4C, EHD2 and GRK1 were involved in 
the KEGG endocytosis pathway (Table 6). We found 
that 28% and 32% of the genes represented by the clas-
sifier proteins contained sequence motifs such as 
coiled coils and ELR motifs at p-values equal to 
0.0004 and 0.003, respectively. An enrichment of the 
protein family domains such as the UBA/TS-N domain 
(ubiquitin associated domain found on the N terminus 
of EF-TS (elongation factor thermo stable)) and the 
TBC domain was also observed. 
Discussion 
 
Peptide microarrays displaying synthetic peptides can 
be used for the detection of antibodies in serum apart 
from their utility in epitope-mapping, substrate profil-
ing and probing peptide-ligand interactions (Andresen 
et al. 2006; Uttamchandani & Yao 2008). In the con-
text of serodiagnostics, peptide arrays have been used 
for the detection of Hepatitis B and C viruses, human 
immunodeficiency virus (HIV), Epstein-Barr virus and 
syphilis (Duburcq et al. 2004).  Li et al. (Li et al. 
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KEGG 
pathways 
p-
value 
Expected 
number 
of genes 
Observed 
number 
of genes 
Genes 
Pentose 
phosphate 
pathway 
0.003 0.06 2 
PGLS, 
ALDOA 
Ribosome 0.003 0.2 3 
RPL7A, 
RPL24, 
RPL6 
Spliceosome 0.04 0.3 2 
ISY1, 
PRPF38A 
Table 5. Over-represented genes from the peptide array 
classifier and the corresponding KEGG pathways 
KEGG 
pathways 
p-
value 
Expected 
number 
of genes 
Ob-
served 
number 
of genes 
Genes 
Endocyto-
sis 
0.006 0.6 4 
GIT1, 
CHMP4
C, EHD2, 
GRK1 
Ribosome 0.04 0.2 2 
RPS3A, 
RPS13 
Table 6. Over-represented genes from the protein array clas-
sifier and the corresponding KEGG pathways 
2010) used peptide arrays with an extracellular domain 
of epidermal growth factor receptor (EGFR) protein 
and detected auto-antibodies against an EGFR domain 
in the sera of non-small cell lung cancer patients. In 
this study, we designed peptides representing sero-
reactive antigenic proteins using the antigenic motif 
search tool. We then used peptide microarrays to iden-
tify the auto-antibody signatures against these peptides 
in the sera of patients with breast cancer and benign 
fibroadenomas as well as healthy females. 
 The prediction of the antigenic peptides was 
performed based on the occurrence of hydrophobic 
residues (cysteine, leucine and valine) in a given pro-
tein sequence (Kolaskar & Tongaonkar 1990). This 
prediction method predicts the antigenic sites with ap-
proximately 75% accuracy. Using the Antigenic tool 
(Selak et al. 2003) we identified antigenic sites within 
the sequence of the early endosome antigen 1 (EEA1) 
protein with antigenic scores ranging from 1.135 to 
1.09. In our study, we used the predicted antigenic mo-
tifs with the antigenic scores ranging from 1.3 to 
0.987. The short peptides, with lengths ranging from 4 
to 15 aa, are effective enough to identify antibody epi-
topes (Reineke & Sabat 2009). In this study, 86.7% of 
the predicted antigenic peptides had varying lengths 
from 7 to 14 amino acids. These peptide sequences 
were used for deducing the individual peptides and for 
the generation of peptide arrays. Peptides with the 
highest sero-reactivity of all the 48 samples showed 
enrichment of motifs similar to Zn-finger domains, 
which can be explained due to the central cysteine be-
ing highly hydrophobic. Moreover, many Zn-finger 
proteins contain variable numbers of Zn-finger do-
mains (Iuchi 2001). These features allowed the Anti-
genic tool to label many of these peptides as antigenic. 
 We have tested another method introduced by 
Wilce and colleagues (1995) to see the correlation be-
tween experimental signal intensities and physic-
chemical properties. The physicochemical parameters 
maximally correlated with the median intensity de-
rived from the peptide arrays. The peptides’ reactivi-
ties were found particularly negatively correlated with 
hydrophobicity while conversely they were positively 
correlated with positive charge, high inter-residue pro-
tein contact energies and possibly a secondary struc-
ture propensity bias. 
 The peptide microarrays were generated using 
synthetic peptides designed with the Antigenic tool 
using cDNA sequences of seroreactive proteins. At the 
same time, protein microarrays were produced using 
the recombinantly expressed proteins from the human 
cDNAs expressed in E. coli. The peptide and protein 
microarrays were used for the evaluation of the same 
set of serum samples. On peptide arrays, classification 
success for distinguishing the 3 classes of malignant, 
benign and control serum samples outperformed pro-
tein arrays during the class prediction analyses. Apart 
from the better sensitivities and specificities, ROC 
analyses on peptide array data provided higher AUC 
values compared to that of protein microarrays (Table 
4 and Figure 7). 
 The binding ability of an antibody to a protein 
largely depends on the conformation at the region of 
binding. The antibodies specific to the proteins have 
the same specificity as long as the binding site is lo-
cated on the surface of the molecule (Geysen et al. 
1985). Expression of recombinant proteins in E. coli 
often leads to the production of misfolded proteins 
(Baneyx & Mujacic 2004). Furthermore, microarray 
immobilization of proteins will dramatically change 
their conformation and accessibility. These effects 
may, in turn, lead to low reproducibility and controver-
sial findings when array-platforms are changed. In our 
study, the possibility of having misfolded proteins im-
mobilized onto protein microarray may have attributed 
to the identification of classifier proteins which did not 
correlate with the results from the peptide microarrays. 
 As performed here, sero-reactive clones were 
identified by a macro-membrane based screening. On 
those membranes, E. coli clones were grown, protein 
expression was induced and the proteins were immobi-
lized directly on the site of clone growth. For elucida-
tion of the diagnostic value of identified antigenic pro-
teins, microarrays provide today’s best option for con-
firmation and validation of thousands of proteins in 
parallel. Biomarker-validation requires analyses of 
many patient samples that would thus be best per-
formed on microarrays. However, switching from the 
macro-membranes used in biomarker identification to 
microarrays requires the isolation of proteins and sub-
sequent spotting on the microarray surfaces. Although 
array-variability due to clone cultivation, protein ex-
pression and immobilization directly on each mem-
brane is omitted when microarrays are generated from 
purified proteins, conditions are dramatically changed 
when moving from macro- to micro-arrays. This might 
also be the reason why protein microarrays in our 
study have shown up with moderate to low classifica-
tion success of malignant breast cancer, benign breast 
nodules and controls. In addition, it has to be noted 
that when sero-reactive clones are discovered from e.g. 
patients and controls, the different TAA-discovery 
technologies like SEREX, macromembranes or phage 
display are currently performed using pooled samples 
rather than many single samples processed in parallel. 
Consequently, even when “differential” TAA profiles 
for different pools of sample classes are discovered, 
these findings are no warranty for any classification 
Journal of Molecular Biochemistry, 2012   139 
success during analyses of single samples. 
 Since the prediction of the antigenic peptides 
was solely based on the protein sequences and each 
peptide presented a single antigenic site, there may be 
a better chance for auto-antibodies to bind specifically 
to a single feature on the microarray. Single spots of 
purified proteins however, might present with multiple 
antigenic sites and would thus enable binding of multi-
ple antibodies. As already mentioned, this might spe-
cifically be the case for multiplexed protein analyses 
when high numbers of different proteins are processed 
under “one” condition. Conformational changes and 
thus presentation and accessibility upon protein immo-
bililzation are hardly controllable and will result in a 
potential mixture of the antigenic sites presented by 
each protein on the protein arrays. This might explain 
why the classifiers from the peptide and protein arrays 
were so different at elucidating varying results. How-
ever, upon comparing the classifiers from peptide and 
protein array class prediction analyses, 9 genes, 
namely PCSK1, DGKK, ZNF598, TBC1D9, 
TMEM199, EPB41L3, SAMD6, PRPF38A and C1orf9, 
were found. Among these proteins, EPB41L3 (Dal1) is 
a tumour suppressor molecule which is often lost in 
various cancers, including breast cancer (Heller et al. 
2007). Zn-finger proteins (represented here as 
ZNF598) are also frequently found to be antigenic 
(Backes et al. 2011). These proteins are usually local-
ised in the nucleus and many of them are expressed 
only during embryogenesis. Thus, overexpression in 
various cancers might be able to elicit immune re-
sponses. Another protein that might be relevant in tu-
mour biology is Dyacilglycerol-kinase-kappa 
(DGKK). Diacylglycerol kinases catalyze the phos-
phorylation of diacylglycerol, which is a key intracel-
lular signalling molecule able to activate protein kinase 
C pathways, one of the most important targets of onco-
therapy (Ron & Kazanietz 1999). 
 Using the genes corresponding to all the clas-
sifiers obtained from peptide and protein arrays, an 
over-representation analysis (ORA) was performed. 
An over-representation of the genes associated with 
spliceosomes was observed in the classifiers from both 
peptide and protein arrays. A plausible explanation for 
this can be deduced from the hypothesis put forward 
by Tan (1989) and Hardin (1986). These authors hy-
pothesise that auto-antibodies often target protein com-
plexes rather than a single protein. One conceivable 
explanation might be that cancer growth and invasion 
releases cell debris into circulation and as a conse-
quence, evokes an immune response. Spliceosomes 
which are involved in alternative splicing may have a 
role in tumourigenesis. Processes like cell cycle con-
trol, signal transduction, angiogenisis, metastasis and 
apoptosis may be affected, as alternative splicing af-
fects the majority of the human genes. Two-thirds of 
all the human gene transcripts are known to undergo 
alternative splicing. Although the function of the en-
coded protein does not alter in most of the cases, some 
may exhibit a malignant phenotype (van Alphen et al. 
2009). 
 ORA of the classifiers from the peptide array 
revealed an over-representation of genes associated 
with the ribosome and the pentose phosphate pathway. 
Like spliceosomes, ribosomes are frequently targeted 
by auto-antibodies (Backes et al. 2011). Apart from 
playing a pivotal role in translational regulation, the 
ribosomal proteins are also associated with processes 
like cellular transformation, tumour growth, aggres-
siveness and metastasis (Zhu et al. 2001). Similarly, 
the pentose phosphate pathway plays an important role 
in tumour proliferation by supplying reduced levels of 
nicotinamide adenine dinucleotide phosphate (NADP) 
and carbons for intracellular anabolic processes in can-
cerous cells (Boros et al. 1998). 
 Over-representation of the genes associated 
with endocytosis was also found among genes corre-
sponding to the protein array classifiers. Deregulated 
expression of the endocytosis proteins may play a role 
in human cancers by affecting the control of cell pro-
liferation. The enhancement of cell replication may be 
promoted through impaired endocytosis as a result of 
prolonged signalling by growth-factor receptors (Floyd 
& De 1998). The genes from the protein array classi-
fier also showed enrichment of the sequence motifs 
such as coiled coils and ELR motifs. These sequence 
motifs may have autoantigenic potentiality (Backes et 
al. 2011; Dohlman et al. 1993). Chemokines with the 
ELR motifs activate the leukocytes, which in turn, trig-
ger an immune response (Strieter et al. 2004). 
 Although recombinant protein expression in E. 
coli has been a method of choice, the process is riddled 
with problems, such as the amount, length and differ-
ent forms of the desired protein to be expressed 
(Baneyx 1999). Expression of recombinant proteins in 
E. coli often leads to the formation of biologically in-
active inclusion bodies (Singh & Panda 2005). Above 
all else, the process of high-throughput recombinant 
protein expression and purification is both time con-
suming and cumbersome. Shorter peptide sequences of 
the protein can recapitulate its biological activity and 
can therefore act as an alternative to a full-length re-
combinant protein (Min & Mrksich 2004).  Synthetic 
peptides can mimic the biological activity of a protein 
and present a simple means for synthesis and manipu-
lation. These peptides are also inexpensive to synthe-
size and are highly stable (Cretich et al. 2006; Uttam-
chandani & Yao 2008). In addition, purified proteins 
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from expression clones may contain a host protein 
background. When using proteins on arrays expressed 
in E. coli, one may encounter the problems associated 
with the E. coli specific reactivity for the evaluation of 
patient sera. With the usage of short synthetic peptides, 
the problem of E. coli or host specific reactivity can be 
avoided. These salient features make them a desirable 
candidate to replace protein arrays. 
 
Conclusion 
 
Protein microarrays were generated using 642 expres-
sion clones found sero-reactive with breast cancer, be-
nign breast tumours and healthy controls in a TAA 
macroarray screen. Antigenic peptides were deduced 
from clone sequences and corresponding peptide mi-
croarrays were produced. Both protein and peptide 
arrays were then processed with serum samples from 
individuals with breast cancer, benign breast tumours 
and healthy controls. Classification success of the 3 
sample groups was moderate using protein microar-
rays. The peptide arrays enabled classification of the 
serum samples with reasonable sensitivities and speci-
ficities. Through the use of peptide arrays, the difficul-
ties associated with the protein arrays can be circum-
vented and thus provide a robust platform for early 
diagnosis of cancer. However, in order to establish 
peptide arrays as a potential breast cancer diagnostic 
tool, test sensitivities and specificities should be in-
creased through additional antigenic peptides which 
then have to be thoroughly validated on larger sets of 
serum samples. This study shows that in silico de-
signed peptides improve the classification success and 
peptide microarrays can thus be a good alternative to 
protein arrays for auto-antibody based biomarker de-
velopment. 
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